Expert: Iran Able to Become Hub of Infertility Treatment in World
“Iran can become the pole of infertility treatment in the world,” said Ali Sadeqi Tabar.
He underlined that Ibn Sina Infertility and Recurrent Miscarriage Treatment Center is ready to patients from all over the world.
Sadeqi Tabar referred to receiving the official license that the Center has received from the Iranian Health Ministry, and said, “This license is considered as a key step in improving the quality of international services of this center and improving the country's position in the field of specialized treatments. We carefully followed the relevant standards and regulations and managed to obtain a high score by complying with all the required indicators.”
Ibn Sina super-specialized center for the treatment of infertility and recurrent miscarriage is one of the distinguished and advanced centers of the country and region in the field of treatment of infertility and recurrent miscarriage.
The center, which was established by Iran and the German university of USHCL in 2003 has been capable of making the life of more than fifteen thousand infertile couples into warm and happy.
Through the efforts of knowledge-based companies and research centers, Iran has become one of the top 10 countries capable of domestically developing know-how and biological sciences to treat infertility and perform In Vitro Fertilization (IVF).
Iranian couples had to travel to European countries for infertility treatment in the past decades, but now many couples from other countries, particularly neighbors come to Iran to receive infertility treatment via IVF.
The country has now become one of the top 10 countries in the world in infertility treatment and the treatment costs in Iran are much lower than in other countries. This has been achieved through the efforts of knowledge-based companies and research-service centers such as highly prestigious Royan Institute.
Based in Tehran, Royan Institute is a renowned center that provides comprehensive services for the infertility treatment, regenerative medicine/cell therapy, production of recombinant proteins and development of biological products.
4155/v
